PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMolgramostim
Molgramostim
Molgramostim is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AA: Colony stimulating factors
— L03AA03: Molgramostim
HCPCS
No data
Clinical
Clinical Trials
2254 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C95101202481028338
LymphomaD008223—C85.978208411226331
Myeloid leukemia acuteD015470—C92.07613735415235
Multiple myelomaD009101—C90.05811522317193
Breast neoplasmsD001943EFO_0003869C50529333127175
Myelodysplastic syndromesD009190—D466110517314170
NeoplasmsD009369—C80797816413168
Non-hodgkin lymphomaD008228—C85.94510323412167
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0448716912148
Myeloid leukemiaD007951—C9234712028119
Show 63 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——1319——328
Fallopian tube neoplasmsD005185——1010——119
GliomaD005910EFO_0000520—138———19
Blast crisisD001752——97——116
Liver neoplasmsD008113EFO_1001513C22.0710———15
OligodendrogliomaD009837EFO_0000631—114———14
Fanconi anemiaD005199Orphanet_84D61.03611——114
Colonic neoplasmsD003110—C1858——111
T-cell lymphomaD016399——28——111
T-cell lymphoma peripheralD016411——19——111
Show 225 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hairy cell leukemiaD007943—C91.43———36
Aids-related complexD000386EFO_0007137B202———24
PinealomaD010871——3————3
Coronary artery diseaseD003324—I25.11———23
LeukopeniaD007970EFO_0004233D72.8192———13
Basal cell carcinomaD002280——2————2
MeningiomaD008579EFO_0003098D32.92————2
Hypertrophic pyloric stenosisD046248—Q40.02————2
Clear cell sarcomaD018227——2————2
VasculitisD014657EFO_0006803M311———12
Show 47 more
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMolgramostim
INNmolgramostim
Description
Molgramostim is a recombinant granulocyte macrophage colony-stimulating factor which functions as an immunostimulator.
Classification
Protein
Drug classcolony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF); colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2109134
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDB321AL142J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 622 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
17 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use